About AbCheck
AbCheck s.r.o., founded in 2009, specializes in custom antibody discovery and screening activities for therapeutic applications. The technology portfolio is based on three different human antibody libraries and covers all aspects of product candidate generation from early stage research to lead optimization. The use of three highly diversified libraries enables AbCheck to isolate highly specific human antibodies against almost any target from a portfolio of over ten billion different antibodies. The company has isolated more than 25 different therapeutic antibody candidates, characterized by high affinity and specificity, against the most difficult targets. AbCheck s.r.o. is a spin-off of Affimed Therapeutics AG based in the Technology Park Pilsen, Czech Republic.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Advertisement
Product portfolio of AbCheck
Here you will find AbCheck s.r.o.
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous